Sernova Corp., a clinical-stage health sciences company focused on commercializing medical technologies, announced it will be presenting at the Biotech Showcase 2013 Conference, taking place Jan. 7-9, 2013, at Parc 55 Wyndham San Francisco – Union Square in San Francisco, Calif. Sernova’s presentation will be given on Monday, Jan. 7 at 1:45 p.m.
Now in its fifth year, Biotech Showcase is an investor and partnering conference focused on providing private and public biotechnology and life sciences companies with the opportunity to meet with, and present to, investors and pharmaceutical executives in one location during one of the largest annual healthcare investor conferences in the industry. Investors and biopharmaceutical executives from across the globe gather in San Francisco each year for this important event.
Sernova, a clinical-stage company developing products that provide a natural and immune-protected environment for delivering therapeutic cells to patients, is currently developing a platform technology for numerous serious disease indications, with its first therapeutic focus on insulin-dependent diabetes. The company is developing two novel, closely integrated proprietary platform technologies: Cell Pouch System, a scalable device that provides a natural, organ-like environment for therapeutic cells such as insulin-producing islets for diabetes; and Sertolin, which is a cell-based technology providing an immune-privileged environment for donor cells – reducing or eliminating the need for anti-rejection drugs. The company holds exclusive rights to multiple patents and associated intellectual property for the therapeutic use of Sertoli cells and has filed patents on the Cell Pouch System.
Sernova’s team is currently focused on developing the Cell Pouch System for treating insulin-dependent diabetes, which could benefit Type-1 and many Type-2 diabetes sufferers, and the company plans to commercialize products for Parkinson’s, spinal cord injury, hemophilia, and other debilitating diseases. Leveraging a medical device and combination product strategy, Sernova takes part in the rapidly expanding cell therapy market and is positioned for significant growth and revenue as its paradigm-shifting technology progresses toward commercialization.
For more information about Sernova, visit www.sernova.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment